Cancers, including those incurable ones, can be treated with a bispecific antibody by allowing T cells to attack the treatment-resistant cancers, scientists claimed. According to Medical Express, since there are too many tumors that do not respond to immunotherapy, it remains an imperfect medical tool.
Results of Phase I trial of JNJ-31186372 EGFR-cMet bispecific antibody show preliminary significant clinical efficacy. Patients experiencing post-osimertinib resistance currently being enrolled! @EGFRResisters #WCLC2018 #lcsm #lungcancer pic.twitter.com/XLTBr70XDB — Ivy Elkins (@ivybelkins) September 25, 2018
Dimitris Skokos and Janelle Waite, the scientists who are part of a large Regeneron team, made advancement in testing a class of co-stimulatory CD28-bispecific antibodies. Since the checkpoint blockade immunotherapy relies on drugs known as immune checkpoint inhibitors, it is already considered as an innovative form of cancer therapy.The scientists designed it to engage the body's T cells to treat multiple forms of cancer, by recognizing and attacking malignant cells.
Also Read: COVID-19: Children Ages 5 and Below May Carry Virus 10 to 100 Times More
This article is owned by TechTimes,
Written by: Giuliano de Leon.
